Retatrutide and knee pain: what TRIUMPH-4 actually showed

TL;DR

• TRIUMPH-4 met both co-primary endpoints at week 68 - a Phase 3 trial in 445 adults with obesity or overweight and knee osteoarthritis, without diabetes.
• Weight loss reached about 28.7% in the higher-dose arm and about 26.4% in the lower, against 2.1% on placebo.
• WOMAC pain fell by as much as 4.5 points (~75.8%) - but placebo fell 2.4 points (~40.3%), so the drug's effect is the difference above that, not the headline figure.
• Complete freedom from knee pain reached 14.1% and 12.0% across the two arms, versus 4.2% on placebo - and the lower arm did slightly better, which is not a clean dose-response.
• The trial cannot isolate an analgesic effect - weight loss and pain relief moved together in the same people, which is inherent to studying a weight-loss agent in weight-related knee pain.
• These are topline press-release figures, not the peer-reviewed paper, and retatrutide remains investigational and not FDA-approved.

Educational content, not medical advice. No doses or protocols appear anywhere; trial arms are identified by rank (higher/lower), never by strength. Retatrutide is investigational and not FDA-approved. Figures are from a topline press release, not the full peer-reviewed paper.

Updated October 2026: re-checked 26 October 2026 against Lilly's 23 July 2026 release, which lists knee osteoarthritis pain among its planned global submissions; this page's framing already matched, so no figures changed. Replaces a supply-verification CTA with a bloodwork-first recommendation.

Updated September 2026: adds the per-arm topline figures (higher dose arm = 28.7%, lower dose arm = 26.4%, placebo = 2.1%) in place of "minimal loss on placebo", and adds the complete-pain-resolution rates with their placebo comparator: 14.1% in the lower dose arm and 12.0% in the higher versus 4.2% on placebo. Note that the widely repeated "one in eight became pain-free" figure is the higher dose arm's from-baseline rate quoted without its placebo arm, and that the lower dose arm did slightly better than the higher on this endpoint. Adds a lastreviewed field, which this file previously lacked._

---

The number doing the rounds - "75.8% less knee pain" - is accurate and easy to over-read, which is exactly the combination that produces bad headlines. TRIUMPH-4 is a genuinely encouraging trial. Understanding what it can and can't establish is the difference between an informed take and "a peptide that cures arthritis," which it is not.

What TRIUMPH-4 measured

TRIUMPH-4 was a 68-week Phase 3 trial in 445 adults with obesity or overweight and knee osteoarthritis, without diabetes. Participants were randomized 1:1:1 to one of two retatrutide dose arms - a higher and a lower - or to placebo, from an average baseline weight of about 112.7 kg (BMI ~40.4). It had co-primary endpoints: percentage change in body weight, and reduction in the WOMAC pain score - a standard osteoarthritis pain measure - both assessed at week 68. Retatrutide is a triple agonist acting on the GIP, GLP-1, and glucagon receptors; the mechanism explainer is in how GLP-1 agonists work.

The headline numbers

Both retatrutide dose arms met both co-primary endpoints. On weight, the higher dose arm lost about 28.7% of body weight (roughly −32 kg / −71 lbs) at 68 weeks and the lower dose arm about 26.4%, against 2.1% on placebo, with nearly half achieving at least 25% loss. On pain, WOMAC scores fell by as much as 4.5 points (up to ~75.8%), compared with a 2.4-point (~40.3%) reduction on placebo. That placebo figure is worth holding onto: a large share of measured pain relief in osteoarthritis trials is typically placebo response, and TRIUMPH-4 is no exception - the drug's effect is the difference above that, not the full 75.8%.

The same care applies to the trial's most-quoted secondary result. At 68 weeks, 14.1% of the lower dose arm and 12.0% of the higher dose arm were completely free of knee pain, against 4.2% on placebo. Coverage has compressed this into "more than one in eight became pain-free," which is the higher dose arm's from-baseline rate reported without its comparator; roughly a third of that figure is matched in the placebo arm. Two further details resist a simple dose-response story: the lower dose arm outperformed the higher on this endpoint, and complete resolution was measured at a single timepoint rather than sustained across the trial. More drug did not mean less pain here.

The confound: weight and pain moved together

Here is the fine print that most coverage skipped. Everyone in the retatrutide arms also lost a large amount of weight - that was the point of the trial. Because weight loss and pain reduction happened in the same people at the same time, the study cannot isolate an independent analgesic effect of the drug. It's not a flaw in the trial; it's inherent to studying a weight-loss agent in people whose knee pain is weight-related. The honest framing is therefore "in people who also lost substantial weight, knee-OA pain fell" - not "retatrutide treats arthritis." Calling it an arthritis drug would claim something the design can't support. For the broader picture of how weight-loss drugs intersect with joint pain, see GLP-1s and joints.

Why a triple agonist might help the knee - as hypotheses

There are two plausible, non-exclusive mechanisms, and both should be read as hypotheses this trial doesn't resolve:

• Mechanical load reduction. Every kilogram lost reduces force across the knee with each step; substantial weight loss plausibly lowers pain for purely biomechanical reasons.
• Metabolic and inflammatory effects. Obesity is a low-grade inflammatory state, and osteoarthritis has an inflammatory component; a drug that improves metabolic health could act on joint biology beyond load. This is mechanistically reasonable and not demonstrated here - TRIUMPH-4 wasn't built to separate it from the weight effect.

Both stories are plausible; probably both contribute; the trial proves neither in isolation.

Where retatrutide actually stands

Retatrutide is investigational and not FDA-approved. TRIUMPH-4 is one readout in the broader TRIUMPH program, and it's reported here from a topline press release - the full peer-reviewed paper, with its subgroup detail and durability data, is still to come, and figures should be re-checked against it when it publishes. Lilly has signalled a regulatory filing around early 2027. In the meantime, retatrutide sits alongside the other next-generation agents mapped in new weight-loss drugs 2026–2027, and its cardiovascular readouts are covered in retatrutide and your heart (TRIUMPH-2/3). The reference for the compound is at Vivre's retatrutide page.

What we still don't know

The open questions are the interesting ones: whether any pain benefit persists independent of weight, how durable the effect is beyond 68 weeks, what the full paper shows on subgroups and safety, and how retatrutide compares head-to-head with existing options for this population. Substantial weight loss also raises the familiar question of protecting lean mass - the GLP-1 muscle-loss question applies here too. None of that is a reason to discount the result; it's a reason to read it as promising rather than settled.

Frequently asked questions

Did retatrutide cure arthritis? No. TRIUMPH-4 showed that in people with obesity and knee OA who lost substantial weight on retatrutide, knee pain fell markedly. Because weight loss and pain relief moved together, the trial can't isolate an independent effect of the drug on the joint - so it's not an "arthritis treatment."

Is retatrutide approved or available? No. It's investigational and not FDA-approved; a regulatory filing has been signalled for around early 2027. TRIUMPH-4 is topline data, not a full published paper.

Is the 75.8% pain reduction the drug's effect? Not entirely. Placebo produced about a 40% WOMAC reduction in the same trial; the drug's specific effect is the difference above placebo, and part of even that is attributable to weight loss rather than a direct action on the knee.

Did one in eight people become pain-free? That figure needs its comparator. At 68 weeks 12.0% of the higher dose arm and 14.1% of the lower dose arm reported complete freedom from knee pain - but so did 4.2% of the placebo arm. The headline quotes a from-baseline rate without the placebo response sitting underneath it. It is also worth noting the lower dose arm did slightly better than the higher on this endpoint, which is not what a clean dose-response would look like.

How is this different from the retatrutide heart data? TRIUMPH-4 is the knee-osteoarthritis trial; the cardiovascular readouts come from TRIUMPH-2/3 in a different population. Both are part of the same Phase 3 program - see retatrutide and your heart.

Related reading

• Retatrutide: the evidence so far · Retatrutide and your heart (TRIUMPH-2/3) · GLP-1s and joints · How GLP-1 agonists work · New weight-loss drugs 2026–2027
• Part of The Complete Guide to GLP-1s

---

Where to start. Retatrutide is investigational and not approved; Vivre Labs' retatrutide page sets out its status. If weight and joint pain are both on your mind, we recommend starting with baseline bloodwork and talking the approved options through with your own doctor.

---

Educational content, not medical advice. Retatrutide is investigational and not FDA-approved. No dose figures appear; trial arms are identified by rank, not by strength. TRIUMPH-4 figures are from a topline press release and should be re-verified against the full peer-reviewed publication. The trial cannot isolate an independent analgesic effect; it is not an arthritis-treatment claim. Claims for the Malaysian market are subject to MAB requirements.

References

• TRIUMPH-4 topline results (Eli Lilly press release, December 2025): Phase 3, 68 weeks, 445 adults with obesity/overweight and knee osteoarthritis without diabetes; randomized 1:1:1 to a higher retatrutide dose arm, a lower retatrutide dose arm, or placebo; baseline ~112.7 kg / BMI ~40.4. · Weight loss higher dose arm ~28.7% (−32.3 kg / −71.2 lbs), lower dose arm ~26.4%, placebo ~2.1%; nearly half achieved ≥25%. · WOMAC pain reduced up to 4.5 points (~−75.8%) vs 2.4 points (~−40.3%) placebo; both co-primary endpoints (weight change + WOMAC pain) met at week 68. · Complete freedom from knee pain at 68 weeks: 14.1% (lower dose arm), 12.0% (higher dose arm), 4.2% (placebo) - the circulating "one in eight" is the higher dose arm's from-baseline rate reported without its placebo comparator. (Patient Care Online; Rheumatology Advisor; Eli Lilly investor release, 11 December 2025.) · Retatrutide: triple agonist (GIP/GLP-1/glucagon); investigational; BLA signalled ~early 2027. · Weight–pain confound inherent to design; topline release, not full paper. · Coverage: Eli Lilly/PR Newswire; Patient Care Online; Healio; Rheumatology Advisor; Pharmacy Times; TRIUMPH design rationale (PMC12673447). Re-verify all figures against the full publication before publishing.